Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.

[Society for Immunotherapy of Cancer @sitcancer]

SITC OnDemand is LIVE! SITC members can access more than 1,000 educational IO videos from past SITC events, webinars, virtual summits, annual meetings & more. Visit https://t.co/cP6BrtKidG #SITCOnDemand #SITCQuestfor100 #MemberBenefit @OncoDailyIO @oncodaily #AACR26 @MoffittNews

[OncoDaily IO @OncoDailyIO]

Beyond PD-1: Exploring the Next Generation of Cancer Immunotherapies – Society for Immunotherapy of Cancer (SITC)

@sitcancer

https://t.co/VWIZtQhaAd

[Society for Immunotherapy of Cancer @sitcancer]

#CIM – On Forward Fund Friday, we recognize the opportunities provided through your donations. Providing Early Career Scientists the funding to develop research through fellowships is helping to shape the future in IO. Contribute & make an impact today. https://t.co/7MjzuWh7Iy

[Society for Immunotherapy of Cancer @sitcancer]

Host–microbe interactions are opening new doors in cancer IO! Join experts Nov. 7 at #SITC26 to examine the microbiome's growing role in cancer development, tumor immunity and response to therapy. Learn more: https://t.co/pYo5JxMzIj
@FrancescaGazza5 @MaayanLevyPhD #CIM @oncodaily

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study" https://t.co/FZCQSlXLVZ

[Society for Immunotherapy of Cancer @sitcancer]

Learn how immune-based approaches are shaping the future of early cancer detection in Webinar 3 of the 2026 SITC Computational IO Series on July 9. Don’t miss insights from leaders in computational IO: https://t.co/hZ2FCezItx

[Society for Immunotherapy of Cancer @sitcancer]

#CIM – It’s Forward Fund Friday. The Steven A. Rosenberg Scholars Award honors Dr. Rosenberg and his critical contributions to IO. Financially supporting this award and other SITC fellowships, helps launch ECS careers. Make a difference, donate today: https://t.co/6ug824pfSQ

[Society for Immunotherapy of Cancer @sitcancer]

@oncodaily @oncodaily Thanks for publishing our post!

[OncoDaily @oncodaily]

One Week Left to Submit Your Regular and Early Career Investigator Award Abstracts to #SITC26!

@sitcancer

https://t.co/RG4H21FBMh

[Society for Immunotherapy of Cancer @sitcancer]

How are the next generation of IO biotech companies being built? Join this opening panel at the NYSE program to hear CEOs and industry leaders discuss funding, innovation, partnerships & growth strategies shaping the future of IO. Registration ends Sunday! https://t.co/KLArQGOaUO

[Society for Immunotherapy of Cancer @sitcancer]

Join leading experts as they explore emerging modalities Beyond PD-1, discussing vaccines, multi-/bi-specific antibodies, & the future of IO drug development. Gain insights from industry leaders & innovators shaping the next generation of cancer IO. https://t.co/TZKfICUeo8

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model" https://t.co/byvkuHuoUr
@filiogloudim

[Society for Immunotherapy of Cancer @sitcancer]

Use our Connect-a-Colleague Tool to refer your colleagues to join #SITC! The top referrer will be recognized at #SITC26. https://t.co/BssOY25MTR

[Dispatch Bio @DispatchBio]

Our CSO Barbra Sasu’s presentation at @sitcancer Spring Scientific is now available to watch, covering how synthetic antigen strategies may enable universal immunotherapies across solid tumors. Tune in below. https://t.co/ftrMRQM80h

[Society for Immunotherapy of Cancer @sitcancer]

Thanks @DispatchBio and to Dr. Sasu for presenting at our Spring Scientific! Hope to see you all at #SITC26

[Dispatch Bio @DispatchBio]

Our CSO Barbra Sasu’s presentation at @sitcancer Spring Scientific is now available to watch, covering how synthetic antigen strategies may enable universal immunotherapies across solid tumors. Tune in below. https://t.co/ftrMRQM80h

[Society for Immunotherapy of Cancer @sitcancer]

@jitcancer @OncoDailyIO @oncodaily @OncologyTimes @endpts

[OncoDaily IO @OncoDailyIO]

Explore Innovative Approaches Targeting PRAME+ Cancers with Cedrik M. Britten – Society for Immunotherapy of Cancer (SITC)

@sitcancer

https://t.co/9gXhICaKZR

[Society for Immunotherapy of Cancer @sitcancer]

@parkerici Thanks for all you do @parkerici - @sitcancer stands with you during #Cancer #Immunotherapy Month and all year long! #CIM #Immune2cancer

[Parker Institute for Cancer Immunotherapy @parkerici]

This Cancer Immunotherapy Awareness Month, we celebrate the scientists, clinicians, patients, and partners advancing one of the most promising approaches in cancer treatment.

Since our founding in 2016, PICI has worked to accelerate the development of breakthrough immunotherapies by bringing together leading researchers, nonprofit partners, and industry collaborators to overcome barriers that have historically slowed progress. Through this unique model, we help move promising discoveries from the laboratory to patients faster.

Every day, we're working to unlock the full potential of immunotherapy and move closer to a future where all cancers are curable.

Read more about our mission and impact here: https://t.co/wqk7gTLPUW

[Society for Immunotherapy of Cancer @sitcancer]

Are you devoted to #makingcurereality? Renew your SITC membership today to continue collaborating with a global network of professionals dedicated to helping improve cancer patient outcomes. https://t.co/mSbmaDw3uV

[Journal for ImmunoTherapy of Cancer @jitcancer]

We're pleased to share that JITC's 2025 Impact Factor increased to 11.7, reflecting the growing reach and citation of work published in the Journal. This metric is one of several indicators of the Journal's performance and engagement. Thank you to our authors, reviewers, editors, and readers for contributing to another strong year for JITC.

Interested in cutting-edge immunology research. Explore JITC: https://t.co/y4LPi8B8aY